Lucid Diagnostics reported $1.3 million revenue in Q1 2026, reflecting nascent market traction of its patented EsoGuard assay paired with the FDA-cleared EsoCheck device for noninvasive early detection of esophageal adenocarcinoma among GERD patients. The November 2024 private placement of $21.975 million senior secured convertible notes underpins liquidity as the company intensifies commercialization and reimbursement efforts, critical for scaling adoption in a sizable at-risk U.S. population. While competitive technology advancements and reimbursement uncertainties persist, Lucid’s unique Collect+Protect sampling method and clinical guideline endorsements provide a defensible position in an emerging molecular diagnostics niche.